TABLE 3

Geometric means and 95% confidence intervals of efavirenz pharmacokinetic parameters on (PK1) and off (PK2) antituberculosis therapy and ratio of geometric means of PK1/PK2 in 32 HIV/TB coinfected children with paired samplesa

ParameterdPK1 GM (95% CI)bPK2 GM (95% CI)P valuecRGM of PK1/PK2 (90% CI)
Tmax (h)2.89 (2.31–3.60)2.52 (2.09–3.05)0.3501.16 (0.89–1.49)
Cmax (mg/liter)4.01 (3.18–5.08)3.37 (2.65–4.27)0.0481.19 (1.03–1.38)
C12h (mg/liter)2.31 (1.69–3.16)1.82 (1.37–2.41)0.0181.27 (1.08–1.50)
Cmin (mg/liter)1.50 (0.93–2.41)1.19 (0.76–1.84)0.3321.26 (0.85–1.89)
AUC0-24h (mg · h/liter)59.19 (44.29–79.11)47.54 (36.44–62.02)0.0191.25 (1.07–1.45)
CL/F (liter/h)4.49 (3.37–5.97)5.79 (4.47–7.51)0.0110.77 (0.66–0.91)
V/F (liter)135.21 (100.43–182.04)162.07 (125.41–209.45)0.2080.83 (0.66–1.06)
t1/2 (h)20.89 (14.42–30.25)19.4 (15.77–23.86)0.6551.08 (0.82–1.42)
  • a PK1, PK on anti-TB therapy; PK2, PK off anti-TB therapy.

  • b GM, geometric mean; RGM, ratio of geometric mean; 95% CI, 95% confidence interval.

  • c P value comparing geometric means between PK1 and PK2.

  • d AUC0–24h, total area under the curve from time 0 to 24 h; C12h, concentration at 12 h post dose; Cmax, peak concentration; Cmin, minimum concentration; CL/F, apparent oral clearance; GM, geometric mean; t1/2 = half-life; Tmax, time to Cmax; V/F, apparent volume of distribution.